[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Regeneron: The Streak Everyone Expects May Finally Require Actual Results

Regeneron Pharmaceuticals (REGN) reports second quarter 2026 earnings tomorrow morning, July 30, before the market opens. With analysts expecting a sharp year-over-year decline in earnings and the stock trading below its 200-day moving average, the central question is whether the biotech giant can stabilize profitability amid what appears to be a challenging operating environment. The options market is pricing a 5% move, while recent earnings have delivered swings averaging over 5%, setting up a potentially volatile reaction.

Regeneron Pharmaceuticals is a leading biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases, with a portfolio anchored by blockbuster drugs including Eylea (eye...

Fundamentals

See More
  • Market Capitalization, $K 73,494,432
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.24
  • Price/Sales 4.92
  • Price/Cash Flow 15.89
  • Price/Book 2.24

Options Overview Details

View History
  • Implied Volatility 39.59% (+0.86%)
  • Historical Volatility 27.17%
  • IV Percentile 75%
  • IV Rank 58.68%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 1) 34.88 (5.02%)
  • Put/Call Vol Ratio 0.77
  • Today's Volume 3,855
  • Volume Avg (30-Day) 1,340
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 40,295
  • Open Int (30-Day) 38,037
  • Expected Range 660.54 to 730.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.00
  • Number of Estimates 6
  • High Estimate $10.21
  • Low Estimate $5.66
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
622.29 +11.75%
on 06/30/26
702.60 -1.02%
on 07/29/26
+63.61 (+10.07%)
since 06/29/26
3-Month
591.52 +17.56%
on 06/02/26
730.59 -4.81%
on 05/13/26
+9.06 (+1.32%)
since 04/29/26
52-Week
541.00 +28.54%
on 10/13/25
821.11 -15.31%
on 01/09/26
+137.27 (+24.59%)
since 07/29/25

Most Recent Stories

More News
Regeneron: The Streak Everyone Expects May Finally Require Actual Results

Barchart Research What to Expect from REGN Earnings REGN Generated July 29, 2026 Current Price $695.42 EPS Estimate $$8.00 Consensus Rating Moderate Buy Average Move 5.43% Regeneron: The Streak Everyone...

REGN : 695.42 (+0.03%)
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman

SAN FRANCISCO , July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 695.42 (+0.03%)
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm

Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout....

REGN : 695.42 (+0.03%)
Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

REGN : 695.42 (+0.03%)
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 695.42 (+0.03%)
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm

NEW YORK , July 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 695.42 (+0.03%)
REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses

A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of...

REGN : 695.42 (+0.03%)
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

Lead Plaintiff Deadline: September 14, 2026

REGN : 695.42 (+0.03%)
INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

SAN FRANCISCO , July 27, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 695.42 (+0.03%)
3 Cash-Heavy Stocks with Questionable Fundamentals

3 Cash-Heavy Stocks with Questionable Fundamentals

WSFS : 80.64 (-1.42%)
OBK : 55.08 (-0.24%)
REGN : 695.42 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 713.28
2nd Resistance Point 707.94
1st Resistance Point 701.68
Last Price 695.42
1st Support Level 690.08
2nd Support Level 684.74
3rd Support Level 678.48

See More

52-Week High 821.11
Fibonacci 61.8% 714.11
Last Price 695.42
Fibonacci 50% 681.05
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.